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Abstract  
AIM: This study evaluated the curative potential of Crinum giganteum in the treatment of 
schizophrenia using an NMDA-receptor antagonist-induced schizophrenic Wistar rat model.  
METHODS: Twenty-five adult Wistar rats of both sexes of average weights 180 g were divided into 
two groups: control and schizophrenic rat models. The controls received 0.1 ml of 0. 9% saline, 
while schizophrenia was induced in models using 25 mg/kg of ketamine hydrochloride (i.p.) for 7 
days. On the 8 day models were divided into group’s k1, k2, k3 and k4 of 5 rats each. K1 and the 
controls were sacrificed then, groups k2 and k3 were treated with 5 mg/kg and 10 mg/kg aqueous 
leaf extract of Crinum giganteum while, k4 (standard) received 25 mg/kg of chlorpromazine orally 
for 28 days. Amygdala were harvested, processed and stained with Haematoxylin and Eosin (H &E) 
stain, Neuron-specific enolase (NSE) marker was also used to monitor the curative effect on the 
amygdala.  
RESULTS: Degenerative changes and increased NSE immunoreactivity were observed in the 
untreated models. Extract-treated models showed normal amygdala and negative NSE 
immunoreactivity while chlorpromazine treated models revealed decreased NSE immunoreactivity. 
CONCLUSION: Crinum giganteum extracts exhibits better curative effect than the standard 
antipsychotic agent. 
 
 
 
 
 
 
Introduction 
 
In the last three decades, herbal agents have 
gained popularity and increased patronage due to 
their folklore use in the management of some disease 
conditions. The world health organisation (WHO) 
indices showed that 1% of the world population 
depend on herbal agents in the treatment of diseases 
including mental disorders such as schizophrenia [1].  
Schizophrenia disturbs thought processes, 
emotions and regulatory mechanisms involved in the 
secretion of neurotransmitters: dopamine, serotonin, 
acetylcholine and glutamate in the limbic areas [2, 3].  
The most widely researched are the 
dopamine hypotheses which implicated diminished 
secretion of dopamine neurotransmitter in the 
neurochemistry of schizophrenia [4-8]. However, the 
glutamate hypothesis of schizophrenia posits 
dysfunction of the N-methyl-D-aspartate (NMDA) 
glutamate receptor in schizophrenia. The NMDA 
receptors are a major subtype of glutamate receptors 
and mediate slow excitatory postsynaptic potentials 
(EPSPs). These slow EPSPs are considered critical 
for the proper expression of complex behaviours, such 
as associative learning, working memory, behavioural 
Basic Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  2                                                                                                                                                                                                                       http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
flexibility and attention which are impaired in 
schizophrenia [4, 5]. In early development, it aids the 
development of neural pathways whose malfunction 
may lead to susceptibility to schizophrenia [1].  
Evidence from basic and clinical researchers 
show that genes associated with the risk for 
schizophrenia influence the modulatory sites on the 
NMDA receptor or intracellular receptor interacting 
proteins that link glutamate receptors to signal 
transduction pathways [9]. A postmortem study 
reported changes in glutamate receptor binding, 
transcription, and subunit protein expression in the 
prefrontal cortex, thalamus, and hippocampus of 
subjects with schizophrenia [10]. Antagonists of the 
NMDA receptor elicit schizophrenic symptoms in 
recreational use or administration of a single low dose 
of such agents [11, 12]  
Phencyclidine (PCP) or ketamine produces 
"schizophrenia-like" symptoms that resemble positive 
(delusion and hallucination), negative (avolition, 
apathy, and blunted affect), and cognitive deficits in 
healthy individuals and rodents [4, 5, 13-16]. In 
addition, the NMDA glutamate receptor regulates the 
function of other neurotransmitter systems implicated 
in the pathophysiology of schizophrenia [17].  
In pharmacotherapy, dopamine transmitter is 
the target of most antipsychotic drugs for 
schizophrenia and NMDA receptor antagonist-induced 
schizophrenia [7]. Generally, antipsychotics are able 
to manage symptoms like delusion, hallucination and 
aggression [18-20]. They are still best described as 
control measures as they do not totally cure the 
mental disorders. Thence, agents that modulate 
glutamate via the NMDA receptors promise to be a 
treatment entity towards the discovery of better 
pharmacological target and agents that could treat 
schizophrenia besides dopamine.  
Crinum giganteum is a major herb used in the 
treatment of mental illnesses in some parts of Africa 
like Cameroun, Niger Republic and Nigeria. In Nigeria, 
it is predominantly used in northern where it called 
gadalli, Albacce Buru or Albacce Dawaddi [21]. 
Traditional medicine practitioners in the region have 
claimed that Crinum giganteum could cure 
schizophrenia and other mental condition [22]. It’s 
been known that herbal agents could have a toxic 
effect, lacks standard formulation and adequate 
dosing regimen [22]. To authenticate this claim, 
scientific evaluation of the plant is necessary; this 
study evaluates the curative potential of aqueous leaf 
extract of Crinum giganteum on the amygdala using a 
NMDA receptor antagonist to induce schizophrenia 
system in Wistar rats.  
This was aimed at ascertaining the curative 
effect using neuron-specific enolase (NSE) marker 
and comparing this property with a standard 
antipsychotic (chlorpromazine) agent.  
 
Materials and Methods 
 
Collection and authentication of plant 
materials 
The leaves were procured from the open 
market and identified by the curator Prof. Mrs M.O 
Nwosu of the Department of Plant Science and 
Biotechnology, University of Nigeria, Nsukka as 
Crinum giganteum. Herbarium sheet was prepared 
and a voucher specimen (UNH/13/401) was deposited 
at the herbarium of same Department.  
 
Preparation of plant extract 
The leaves were washed with distilled water 
and air-dried under shade for seven days. Thereafter, 
the leaves were pulverised into a fine powder, 100 
grammes of the dried leaf powder was placed in a 
beaker containing 500ml of distilled water. The 
mixture was heated on a hot plate with continuous 
stirring at 30 ºC -40ºC for 20 minutes. It was then 
allowed to cool and then filtered through mesh cloth. 
The filtrate (aqueous extract) was evaporated to a 
paste using a vacuum evaporator. This was 
transferred into a suitable container and kept in the 
refrigerator at low temperature (4 ºC) for the 
experiment. 
 
Animals and ethical concern 
Twenty-five (25) adult Wistar rats of both 
sexes of average weights 180 g were purchased from 
the animal house of the College of Medicine. The 
university of Nigeria, and housed at the animal facility 
of the same college. The animals were housed in 
netted iron cages in groups of five, fed with grower's 
mash and provided water ad libitum. The rats were 
maintained under laboratory conditions (temperature 
24±2 
o
C with relative humidity 60-70%, and 12-hour 
light-dark cycle). They were acclimatised for two 
weeks before the experiment. The experimental 
protocols and techniques used in the study were in 
accordance with accepted principles for laboratory 
animal use and care. The study was reviewed and 
approved by the University Health Research Ethics 
Committee with certificate number 
NKREC/05/01/2008B-FWA00002458-1RB00002323.  
 
Induction of schizophrenia in rat models  
Twenty (20) rats were induced using 25 
mg/kg ketamine hydrochloride (a NMDA receptor 
antagonist) per body weight, intraperitoneal (i.p), for 7 
days. The control (group A) had 5 rats which received 
0.1ml 0.9% saline. The animals exhibited side to side 
head rocking and continuous staggering locomotion. 
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Treatment of animals and tissue 
processing 
On the 8 days, the ketamine group (n = 20) 
was divided into four groups (k1-k4). The control 
(group A) and group k1 (untreated model) were 
sacrificed same day. Groups k2 and k3 received 5 
mg/kg and 10 mg/kg of aqueous leaf extract of gadalli 
orally respectively, while group k4 received 25 mg/kg 
of chlorpromazine orally for 28 days. The rats were 
anaesthetized with 50 mg/kg thiopental sodium and 
aortic perfusion fixation with 4% paraformaldehyde 
was carried out. The brains were dissected out and 
further fixed in 4% paraformaldehyde overnight, 
amygdala was harvested. Fixed tissues were 
dehydrated in ascending grades of ethanol (50%, 
70%, 90% and 100%), cleared in xylene and 
embedded in paraffin wax. Serial sections of 10µm 
thick were obtained using a rotatory microtome. Part 
of the paraffinized sections was stained using 
haematoxylin and eosin (H &E) and the rest were 
used for the immunohistochemical study.  
 
Immunohistochemical demonstration of 
NSE 
The Avidin-Biotin Complex (ABC) method 
also referred to the Avidin-biotin Immunoperoxidase 
method was used. Paraffin processed tissues were 
sectioned at 2 microns on the rotary microtome and 
placed on the hot plate at 70 degrees for at least 
1hour. Sections were brought down to water by 
passing the on 2 changes of xylene, then 3 changes 
of descending grades of alcohol (100%, 90%, 70% 
and 50%) and finally to water. Antigen retrieval was 
performed on the sections by heating them in a citric 
acid solution of PH 6.0 using the microwave at power 
100v for 15 minutes. The sections were equilibrated 
gradually with cool water to displace the hot citric acid 
for at least 5 minutes for the section to cool. 
Peroxidase blocking was done on the sections by 
simply covering sections with 3% hydrogen peroxide 
for 15 mins. Sections were then washed with 
phosphate-buffered saline (PBS) and protein blocking 
was performed using avidin for 15 mins. Sections 
were washed again with PBS and endogenous biotin 
in tissues was blocked using biotin for 15 mins.  
After washing with PBS sections were 
incubated with the respective diluted primary antibody 
NSE antibody (diluted 1:100) for 60 mins. Excess 
antibodies were washed off with PBS and a 
secondary antibody (LINK) was applied on the section 
for 15 min. Sections were washed and the (LABEL) 
which is the horseradish peroxidase (HRP) was 
applied on all sections for 15mins. A working DAB (3, 
3’-diaminobenzidine) solution was made up by mixing 
1 drop (20 microns) of the DAB chromogen to 1ml of 
the DAB substrate. This working solution was applied 
on sections after washing off the HRP with PBS for at 
least 5mins. The brown reactions begin to appear at 
this moment especially for positive targets. Excess 
DAB solution and precipitate were washed off with 
water. Sections were counterstained with 
Haematoxylin solution for at least 2 mins and blued 
briefly. Sections were dehydrated in alcohol, cleared 
in xylene and mounted in DPX. 
 
 
Results  
We can see from the Figure 1 that sections of 
amygdala of rats (a) control (0.1ml saline) shows 
normal neurons, (b) untreated schizophrenic model 
(25 mg/kg ketamine) shows cytoplasmic vacuolations, 
(c) and (d) schizophrenic models treated with 5 mg/kg 
and 10 mg/kg of ethanolic leaf extract of Crinum 
giganteum shows  normal neurons respectively, and 
(e) schizophrenic model treated with 25 mg/kg of 
chlorpromazine shows relatively normal neuron. 
 
Figure 1: Sections of amygdala of rats (a) control (0.1ml saline), (b) 
untreated schizophrenic model (25 mg/kg ketamine), (c) and (d) 
schizophrenic models treated with 5 mg/kg and 10 mg/kg of 
ethanolic leaf extract of Crinum giganteum, and (e) schizophrenic 
model treated with 25 mg/kg of chlorpromazine.Arrows. (H&E) x 
200 
Sections of amygdala of rats (a) control (0.1ml 
saline) show negative immunoreactivity, (b) untreated 
schizophrenic model (25 mg/kg ketamine) shows 
positive NSE immunoreactivity, (c) and (d) 
schizophrenic models treated with 5 mg/kg and 10 
mg/kg of ethanolic leaf extract of Crinum giganteum 
shows NSE negative immunoreactivity respectively, 
and (e) schizophrenic model treated with 25 mg/kg of 
chlorpromazine shows positive NSE immunoreactivity 
(Figure 2).  
 
Figure 2: Sections of amygdala of rats (a) control (0.1ml saline), (b) 
untreated schizophrenic model (25 mg/kg ketamine), (c) and (d) 
schizophrenic models treated with 5 mg/kg and 10 mg/kg of ethanolic leaf 
extract of Crinum giganteum, and (e) schizophrenic model treated with 25 
mg/kg of chlorpromazine. NSE x 200 
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Discussion 
 
In this study, ketamine-induced neuronal 
damage was characterised by cytoplasmic 
vacuolation and eccentric nuclei. Ketamine induction 
of vacuolation and neuronal cell death in rodents has 
been established [7, 23, 24]. This is possible 
considering the mechanisms propounded from 
previous studies via inhibition or antagonism of N-
Methyl-D- Aspartate (NMDA) receptors [23, 24].  
Compensatory upregulation of NMDA 
receptor expression, which is tied to the toxic influx of 
calcium and elevated reactive oxygen species (ROS) 
generation and neuronal cell death [25, 26]. Another 
mechanism involves blockade of an excitatory NMDA 
glutamate receptor on the GABA neurones, which 
could trigger decrease GABA release and activate 
compensatory increase blood flow and metabolism 
[27]. Ketamine neurotoxicity also triggers induction of 
heat shock proteins (Hsp70) and denaturation of 
intracellular proteins in pyramidal neurones [27-29]  
The neuronal damage (ketamine 
neurotoxicity) observed in the untreated schizophrenic 
models was attenuated by treatment with the varying 
doses of the extract of crinum giganteum. Meanwhile, 
the standard antipsychotic treatment showed relatively 
normal neurone which was less prominent compared 
to the extract treatment. Their potential or degree of 
the effects can further be deduced from the NSE 
immunoreactivities. 
Neuron-specific enolase (NSE) is expressed 
in all neuronal cell types, its detection has been used 
to identify neuronal cells and monitor disease 
progress in the CNS [30]. The untreated 
schizophrenic rat models showed positive and 
increased expression of NSE which confirms the 
neuronal damage earlier reported in the group. This 
was consistent with increased NSE levels seen in 
acute neuronal injury in the area of the brain [31]. The 
negative NSE immunoreactivity in the extract treated 
groups and the verisimilitude with the control attest to 
that fact that ketamine effect was reversed and the 
amygdala integrity was restored. However, curative 
effect of the standard antipsychotic treatment 
(chlorpromazine) was less compared to the extract 
treatment going by the positive but decreased NSE 
immunoreactivity.  
We attributed the effect of the extract to the 
phytochemicals present in the aqueous leaf extract of 
crinum giganteum such as alkaloids, saponins and 
glycosides. Saponins generally exhibit antioxidant 
activity and ginsenosides saponins are known to 
foster neurogenesis [23, 32]. Similarly, glycosides 
possess neuroprotective effect [33, 34], which must 
have played a role in the reversal effect of the extract. 
The activities of these phytochemicals in the extract 
have conferred neuroprotective effects by attenuating 
effect of the NMDA receptor antagonist (ketamine) in 
the treated schizophrenic rat models. 
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